Glucagon is an antihypoglycemic agent. It is available as injection, kits and powder for intravenous, subcutaneous and intramuscular use. MedsAcross supplies Glucagon for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Glucagon for Injection is an antihypoglycemic agent and a gastrointestinal motility inhibitor indicated: for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients
Source: US FDA prescribing information
Glucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect. Extrahepatic effects of glucagon include relaxation of the smooth muscle of the stomach, duodenum, small bowel, and colon.
Source: US FDA prescribing information
Dosage in adults and pediatric patients using the glucagon emergency kit for low blood sugar to treat severe hypoglycemia. Adults and Pediatric Patients Weighing More Than 25 kg or for Pediatric Patients with Unknown Weight 6 Years and Older: - The recommended dosage is 1 mg (1 mL) injected subcutaneously or intramuscularly into the upper arm, thigh, or buttocks, or intravenously. - If there has been no response after 15 minutes, an additional 1 mg dose (1 mL) of Glucagon for Injection may be administered using a new kit while waiting for emergency assistance.
Source: US FDA prescribing information
Glucagon for Injection is contraindicated in patients with: Pheochromocytoma Insulinoma because of the risk of hypoglycemia Known hypersensitivity to glucagon or any of the excipients in Glucagon for Injection. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension Glucagonoma because of risk of hypoglycemia when used as a diagnostic aid Pheochromocytoma. Insulinoma. Known hypersensitivity to glucagon or to any of the excipients. Glucagonoma when used as a diagnostic aid
Source: US FDA prescribing information
Catecholamine Release in Patients with Pheochromocytoma: Contraindicated in patients with pheochromocytoma because Glucagon for Injection may stimulate the release of catecholamines from the tumor. Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose, however, Glucagon for Injection may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. If a patient develops symptoms of hypoglycemia after a dose of Glucagon for Injection, give glucose orally or intravenously. Hypersensitivity and Allergic Reactions: Allergic reactions have been reported and include generalized rash, and in some cases anaphylactic shock with breathing difficulties, and hypotension.
Source: US FDA prescribing information
The following important adverse reactions are described below and elsewhere in the labeling: Hypersensitivity and Allergic Reactions Necrolytic Migratory Erythema Hyperglycemia in Patients with Diabetes Mellitus when Used as a Diagnostic Aid Blood Pressure and Heart Rate Increase in Patients with Cardiac Disease when Used as a Diagnostic Aid Most common adverse reactions ( >5% or greater incidence): Injection site swelling, injection site erythema, vomiting, nausea, decreased blood pressure, asthenia, headache, dizziness, pallor, diarrhea, and somnolence.
Source: US FDA prescribing information
Beta-blockers: Patients taking beta-blockers may have a transient increase in pulse and blood pressure. Indomethacin: In patients taking indomethacin Glucagon for Injection may lose its ability to raise glucose or may produce hypoglycemia. Anticholinergic drugs: Concomitant use of anticholinergic drugs with Glucagon for Injection for use as a diagnostic aid is not recommended. Warfarin: Glucagon for Injection may increase the anticoagulant effect of warfarin. Insulin: Monitor blood glucose when Glucagon for Injection is used as a diagnostic aid in patients receiving insulin.
Source: US FDA prescribing information
Do not freeze. Storage Before Reconstitution The package containing Glucagon for Injection vials may be stored up to 24 months at 20° to 25° C (68° to 77° F) prior to reconstitution. Keep in the original package to protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
9 presentations of Glucagon, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Baqsimi 3 mg powderNasal | Amphastar Pharmaceuticals | US FDA | Available on request |
| Glucagon kitGeneric name | — | US FDA | Available on request |
| Glucagon 1 mg/mL powder for injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Gvoke HypoPen 0.5 mg Auto-Injector 0.5 mg/0.1 mL injectionSubcutaneous | Xeris Pharmaceuticals | US FDA | Available on request |
| Gvoke HypoPen 1 mg Auto-Injector 1 mg/0.2 mL injectionSubcutaneous | Xeris Pharmaceuticals | US FDA | Available on request |
| Gvoke PFS 1 mg Pre-filled Syringe 1 mg/0.2 mL injectionSubcutaneous | Xeris Pharmaceuticals | US FDA | Available on request |
| Gvoke VialDx 1 mg/0.2 mL injectionIntravenous | American Regent | US FDA | Available on request |
| Glucagon kitIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Gvoke Kit 1 mg/0.2 mL injectionSubcutaneous | Xeris Pharmaceuticals | US FDA | Available on request |
6 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 9 presentations of Glucagon and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 6 brand names for Glucagon, including Baqsimi, Gvoke HypoPen 0.5 mg Auto-Injector, Gvoke HypoPen 1 mg Auto-Injector, Gvoke Kit, Gvoke PFS 1 mg Pre-filled Syringe, Gvoke VialDx.
Yes. The US FDA first approved Glucagon on 14 November 1960, according to Drugs@FDA.
Yes. Glucagon has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Glucagon is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Glucagon is classified under ATC code H04AA01 (Glucagon).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.